Registro de fuente primaria
Grado decisivoResultados principales
Quince Therapeutics: Datos de fase 2b PH-ILD para LAM-001 esperados en el primer trimestre de 2028
La adquisición de Orphai Therapeutics añadió LAM-001 a la cartera de Quince. Un ensayo de fase 2b con 75 pacientes en PH-ILD está en curso, con resultados principales previstos para el primer trimestre de 2028. Un ensayo de fase 2 separado en BOS está completamente reclutado, con resultados esperados en el primer trimestre de 2027.
Datos clave
Extracto de la fuente
EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann